BACKGROUND: One of the most well-documented cytokines suspected as a hazard to male fertility is tumor necrosis factor-a (TNFa). Genetic factors such as single-nucleotide polymorphisms (SNPs) in the TNF gene cluster impact TNFa levels. Our objective was to establish the potential involvement of 2308 TNF SNP in male infertility risk. METHODS: In 684 infertile male patients undergoing an intracytoplasmic sperm injection procedure, we used allele-specific polymerase chain reaction (PCR) and PCR-RFLP to investigate the distribution of the guanine (G)-to-adenosine (A) substitution at position 2308 in the promoter region of the TNFa gene. RESULTS: An increased frequency of the 2308 TNFa A allele was found in patients with low sperm count of testicular origin [P 5 0.002; odds ratio (OR) 5 2.93] or with normal production count but altered sperm motility (P 5 0.003; OR 5 2.32), compared with a patient group with normal sperm count and quality (morphology and motility). In patients with low sperm count exhibiting TNFa A allele, compared with those with G allele, an alteration in hormonal balance was observed with increased inhibin B levels and subsequent reduced FSH plasma levels, leading to an FSH/inhibin B ratio roughly half as high (from 0.07 + + + + + 0.01 in TNFA versus 0.13 + + + + + 0.02 in TNFG allele groups, P < 0.0001). CONCLUSION: As the 2308 TNFa A allele has been associated with an increased expression/production of TNFa, the potential use of therapies based on inhibition of TNFa activities could represent possible therapeutic opportunities for patients with low sperm count (i.e. primary testicular dysfunction) or with altered sperm motility.
Introduction
Approximately 15% of couples attempting their first pregnancy meet with failure. A male impairment is present in $50% of infertile couples, suggesting that male infertility affects $7% of couples around the world (Thonneau et al., 1991) . Although several causes have been identified for impaired male fertility (endocrine dysfunction, post-testicular obstruction, vascular abnormalities, genetic or congenital factors, antispermatogenic agents), little progress has been made in the development of treatment modalities for male infertility (Liu and Handelsman, 2003) . Paradoxically, despite this lack of treatment modalities, there has been an explosive growth in the use of various medically assisted reproduction techniques (ART) such as intracytoplasmic sperm injection (ICSI) that have allowed sub-or infertile men to initiate conception without attempting to improve their fertility status with therapies related to the cause(s) of their infertility. In addition, the use of ART is associated with potential genetic risks. Indeed, when treating infertile couples, the ART methods, in particular the ICSI method, potentially enable the hereditary transmission of infertility and other impaired genetic conditions to offspring (Devroey and Van Steirteghem, 2004; Woldringh et al., 2005) .
Among the therapeutic approaches used to bypass or complete the use of ART is hormonal therapy for infertile patients. However, endocrine therapies are very often insufficient to significantly improve the fertility status of infertile men. This is probably due to the fact that we are still unable to identify the subsets of infertile men who might benefit from these therapies. In this context, our present study aims at identifying subsets of infertile patients according to their specific genetic polymorphisms and particularly cytokine polymorphisms; these patients may therefore potentially benefit from new and/or more appropriate therapeutic opportunities.
Spermatogenesis depends upon numerous local signaling molecules, which provide integration and communication among the different cell types in the testis during hormonal regulation of germ cell maturation. This local regulatory control is supported by a large number of cytokines (Benahmed, 1996; Petersen et al., 2004) , among which is the tumor necrosis factor-a (TNFa). In the testes, TNFa receptors (p55) are present in Sertoli and Leydig cells (Mauduit et al., 1996) , allowing TNFa to modulate their functions. In experimental models, TNFa affects both gonadotrophin production and action in the male reproductive function and reduces male fertility (Mauduit et al., 1993 (Mauduit et al., , 1998 Benahmed, 1996; Kalra et al., 1998; Huleihel and Lunenfeld, 2004) . Some studies have shown TNFa levels to be negatively correlated with sperm motility and morphology (Eisermann et al., 1989; Kocak et al., 2002) . Genetic factors may impact TNFa levels, and several polymorphisms in the TNF gene cluster have been associated with modified TNFa production (Hajeer and Hutchinson, 2001 ). The TNFa gene cluster is located within the class III region of the highly polymorphic major histocompatibility complex on chromosome 6p21. The TNFa gene lies between the lymphotoxin a (TNFb) and LTB genes (Nedwin et al., 1985) . There are many polymorphisms within the TNF gene cluster. So far, six single-nucleotide polymorphisms (SNPs) have been described in the 5 0 region of the TNFa gene, including -238 and -308 G/A SNPs. The 2308 G/A SNP is the most commonly studied polymorphism. This SNP, located at nucleotide 2308 with respect to the TNF transcriptional start site, substitutes guanine for adenine, and allelic types are referred to as 2308G/2308A (Wilson et al., 1992) . In the literature, frequency of the A allelic type varies greatly in different populations, e.g. from 0 (Hohjoh et al., 1999) to 51.3% (Yucesoy et al., 2002) . Although in French studies the frequency of the SNP appears to be $25%, these studies relate to specific pathologies including non-Hodgkin's lymphoma (Warzocha et al., 1998) , coronary heart disease (Herrmann et al., 1998) , pneumoconiosis (Nadif et al., 2003) and metabolic syndrome (Meirhaeghe et al., 2005) . However, it should be noted that in all these patient groups, the fertility and endocrine status of the patients are not known. For these reasons, in order to identify a possible association between the presence of the -308 A TNFa allelic type and male infertility, specifically with impaired spermatogenesis, it was more appropriate to determine the distribution of the TNFa polymorphism among the different subsets of patients exhibiting various infertility etiologies. Specifically, we have evaluated the TNFa polymorphism frequency in patients with low sperm count, with or without an obstructive origin, and normal sperm count, with or without morphological or functional alterations.
Materials and Methods

Experimental subjects
Men with primary infertility for at least 1 year (684 patients: 257 from Lyon and 427 from Poissy, with an average age of 36.1 + 0.2 years) who required ICSI procedures were eligible for the present study. Infertile patients had undergone extensive evaluation, including family and personal history, physical and/or ultrasonographic examination, biochemical seminal parameters (carnitine, fructose and citric acid), karyotype, Y deletion and histological testicular analysis for azoospermic patients. Sperm parameters were evaluated according to standard criteria (WHO, 1999 Infertile patients were classified into four groups before -238 and -308 TNFa polymorphism genotyping (Table I) . Ethnicity of the patients (mainly from the Caucasian and North African origin) was similar for all four study groups. Major exclusion criteria were age (.50 years), vasectomy, endocrine pathology (hypogonadotropic hypogonadism), hormonotherapy, toxic habits (tobacco, more than 40 cigarettes per day; alcohol and/or drug abuse), immunosuppressive or chronic chemotherapy treatments, unilateral orchidectomy, abnormal karyotype, Y chromosome deletions and chronic genital infections.
ASPCR and PCR-RFLP analyses
Genomic DNA was extracted from subjects' blood samples using the Wizardw Genomic DNA Purification Kit (Promega, Southampton, UK). A TNF-R primer (5 0 -TCTCGGTTTCTTCTCCATCG) was used with either 308-G (5 0 -ATAGGTTTTGAG GGGCATGG) or 308-A (5 0 -ATAGGTTTTGAGGGGCATGA) to amplify a 184 bp fragment of the TNFa gene, which includes the polymorphic site at the nucleotide position 2308. The primer pair TNF-F (5 0 -GAGT CTCCGGGTCAGAATGA)/TNF-R was used to amplify a 531 bp TNF gene fragment that was used as an internal control in the allelespecific polymerase chain reaction (ASPCR). Primer TNF-F was also used as a competitor for the TNF-R/A and TNF-R/G primer pairs to improve the specificity of the ASPCR assay (Zhu and Clark, 1996) . After initial heating at 958C for 10 min, 30 PCR cycles were performed and consisted of heat denaturation (958C for 45 s), annealing (for 150 s at 608C for the TNF primer pair) and extension (728C for 45 s). A final extension (728C for 9 min) was performed. PCR products for -308 A/A, G/G or G/A patients were checked by direct sequencing on an automated ABI Prism 377 DNA Sequencer (Applied Biosystems, Perkin Elmer; Foster City, CA, USA). Similarly, a TNF-R primer (5 0 -TCTCGGTTTCTTCTCCATGG) was used with either 238-G (5 0 -GAAGACCCCCCTCGGAACCG) or 238-A (5 0 -GAAGACCCCCCTCGGAATCA) to amplify a 115 bp fragment of the TNFa gene, which includes the polymorphic site at nucleotide position -238. The TNF-F (5 0 -GAGTCTCCGGGTCA GAATGA)/TNF-R primer pair was used to amplify a 533 bp TNF gene fragment that was used as an internal control in the ASPCR. Accession numbers were rs1800629 and rs361525 for the -308 and -238 TNFa SNPs, respectively. A PCR-RFLP approach was also performed for all the patients to evaluate -308TNFa polymorphism. The 5 0 region of TNFa gene (2331 to þ14) was amplified according to Huang's report (Huang et al., 1997) . The PCR products were digested with NcoI and analyzed on a 2% MetaPhor agarose gel. DNA products were visualized by ethidium bromide staining. The TNF 2308G allele would be digested into two fragments (325 and 20 bp), whereas TNF 2308A allele would not be digested (345 bp).
Endocrine analyses LH and FSH plasma levels were measured using Elecsys-LH and Elecsys-FSH kits (Roche, Germany), respectively. Serum inhibin B was measured using an Inhibin B Dimer Assay Kit (Argene Biosoft, France). The detection limit was 18 pg/ml, and the intra-and interassay coefficients of variation were 15 and 18%, respectively. Total plasma testosterone (Tt) was measured by radioimmunoassay after organic extraction and chromatographic pre-purification on Celite columns (Rinaldi et al., 2001) . The intra-and interassay coefficients of variation were both ,8%. The concentration of T (TnL) that was not bound to SHBG in plasma (free Tþ albumin-bound T) was quantified by measuring the T in the supernatants of plasma samples after precipitation with 50% saturated ammonium sulfate (Dechaud et al., 1989) . The interassay variation coefficients were ,12%. SHBG assays were carried out with an SHBG-RIACT kit (CIS Bio International, Gif-sur-Yvette, France).
Statistical analysis
The prevalence of genotypes involving the -308A TNFa allelic types was compared between patients who exhibited decreased sperm counts (Groups I, II and III) and those with normal sperm counts (different four subgroups) using an unconditional logistic regression model (Breslow and Day, 1980) . Nested models were compared using likelihood ratio test. The association between groups and genotypes was analyzed using odds ratio (OR) with 95% confidence intervals (95% CI). Statistical tests (two-tailed) with a P-value ,5% were considered as significant. The Mann-Whitney U-test was used to analyze FSH, LH, inhibin B, free and total T and SHBG levels in patients with obstructive and non-obstructive oligo-or azoospermia according to the presence or absence of the -308A TNFa allelic types; P-values were corrected using the Bonferroni method.
Results
Increase in 2308A allelic type frequency in infertile patients with decreased spermatozoa production or altered motility The SNP investigated here by allele-specific PCR is a guanine (G)-to-adenosine (A) substitution at position -308 in the promoter region of TNFa gene. ASPCR data were checked by using direct sequencing and the RFLP-PCR approach; representative results are shown in Fig. 1 . No discrepancies were observed in 2308 TNFa SNP incidence between the ASPCR and the RFLP-PCR approaches. -308A TNFa SNP was analyzed both in the entire population (Table II, Fig. 2 ) and in the population with a Caucasian ethnic origin (Table III, Fig. 3 ). In Table II and Fig. 2A , the data indicate a higher frequency of -308A TNFa SNP in infertile patients with nonobstructive oligo-or azoospermia (Group II) compared with (i) patients with oligo-or azoospermia of obstructive origin (Group I) (30.9 versus 13.2%, OR ¼ 2.93, 95% CI 1.39 -6.20) and with (ii) patients with normal sperm parameters (i.e. Group IV A2T2) (30.9 versus 19.4%, OR ¼ 1.86, 95% CI 1.07-3.23, P ¼ 0.024). Similar observations were noted in the Caucasian population, where patients with oligo-or azoospermia of non-obstructive origin exhibit a significantly higher (31.2 versus 17.7%) (II versus IV A2T2 Caucasian OR ¼ 2.10, 95% CI 1.16 -3.83, P ¼ 0.011) frequency of the -308A allele type (Table III and Fig. 3 ). On the other hand, compared with the patient group with normal parameters (Group IV A2T2), patients from Group I with altered sperm count owing to obstructive origin exhibited a lower, but not significantly lower (13.2 versus 19.4%, OR ¼ 0.63, 95% CI 0.27-1.49, P ¼ 0.29) -308A allelic type frequency. Similarly, in the Caucasian population, Group I patients exhibited a lower, but not significant lower, (12.9 versus 17.7%) (I versus IV A2T2 Caucasian OR ¼ 0.69, 95% CI 0.28 -1.79, P ¼ 0.44) frequency of the TNFa polymorphism. The frequency of the -308A allele was also higher in infertile patients with altered sperm motility (subgroup IV Aþ) compared with patients with normal sperm motility (32.9 versus 17.5% OR ¼ 2.32, 95% CI 1.32-4.09). No difference in 2308A TNFa allelic type frequency was observed in the patients exhibiting abnormal sperm morphology (Tþ) compared with patients with normal sperm morphology (T2). In Table III and Fig. 3 , upon examination of -308A TNFa SNP frequency in the infertile patient population according to ethnic origin, a comparable distribution of the cytokine polymorphism was observed in the Caucasian population according to the subset of male infertilities. Once again, a higher frequency of -308A TNFa SNP was observed in patients with oligo-or azoospermia with primary testicular failure compared with those with obstructive azoospermia (31.2 versus 12.9%) and with patients with normal sperm parameters (31.2 versus 17.7% Group IV A2T2). A higher frequency of the -308A TNFa SNP also occurred with asthenospermia (34.3 versus 16.2%). Owing to the limited number of infertile North African patients, we were not able to perform statistical analyses on this population. Finally, it should be noted that the number of homozygote patients was very small, representing 1.5% of all patients (10/684) and 5.7% of patients exhibiting -308 TNFa polymorphism. Because of this, both AA and AG allelic types were analyzed together. The analysis of the -238 TNFa polymorphism indicates that 12.5% of the entire population exhibits this SNP and that 16.2, 12.4 and 14.3% of the patients from Groups I, II and III, respectively, exhibit this SNP. There was no statistical difference in the percentage of patients exhibiting the -238 TNFa SNP among the three groups with decreased sperm count. Similarly, there was no statistical difference in the percentage of patients with normal sperm counts (in the four subgroups of Group IV, i.e. with normal sperm counts; data not shown).
Hormonal pattern changes in patients with non-obstructive oligo-or azoospermia exhibiting 2308A TNFa polymorphism The gonadotrophins (FSH and LH), testosterone (total and free T), SHBG and inhibin B plasma levels were evaluated in the different groups of patients. Among the patient groups with decreased sperm count, Group I, as expected, showed a normal hormonal pattern that is consistent with the absence of alterations in the spermatogenetic process, whatever the genotype (Table IV) . In Group II patients, without regard to genotype, the association of a decrease in inhibin B plasma levels and an increase in FSH clearly supports the non-obstructive origin (i.e. primary testicular failure of the spermatogenetic process) of the low sperm count. However, in this group, the hormonal pattern and specifically FSH and inhibin B plasma levels were differently affected depending on the 2308A allele. In Group II patients with the 2308A allele compared with those with the 2308G allele, inhibin B plasma levels were significantly (P ¼ 0.0017) higher (Table IV) , leading to FSH plasma levels which were significantly (P ¼ 0.0027) lower compared with patients exhibiting the 2308G allele. More specifically, the ratio of FSH to inhibin B dropped from 0.13 + 0.02 in patients with 2308G allele to 0.07 + 0.01 in the presence of the 2308A allele (P , 0.0001). LH, total testosterone and SHBG plasma levels were not affected in Group II patients whatever the genotype, except for a very limited (127 + 5.5 versus 105 + 3.5) but significant (P ¼ 0.0005) higher level of free testosterone. This level was observed in Group II patients in the presence of 2308A allele. When considering GG, AG and AA patients separately, an allelic rate influence on hormone levels can be noted. For example, for FSH levels, the values were 15.7 + 0.9, 11.4 + 0.9, 11.7 + 1 and 8.5 + 2.4 in the presence of G/G, A/ GþA/A, A/G and A/A alleles, respectively. For inhibin B levels, the increase is also dependent on the A allele rate from 60 + 4 (G/G), 94.3 + 8.09 (A/GþA/A), 91.7 + 8.3 (A/G) to 107.7 + 38.2 (A/A) (Fig. 4) . In terms of statistical data analysis, although there were statistically significant differences between AG and GG genotypes, no statistical difference could be observed between GG and AA genotypes (except for free testosterone), due probably to the small number of AA genotype patients (n ¼ 65).
Discussion
Although TNFa 2308 polymorphism is considered a potential risk factor when associated with pathological attacks including arthritic or other inflammatory diseases, infection or autoimmune diseases (Abraham and Kroeger, 1999) , there has been no study concerning the potential role of 2308A TNFa polymorphism in infertility, particularly male infertility. The aim of this study was to examine the genotype distribution of 2308 TNFa gene polymorphism in 684 male patients suffering from infertility with various etiologies and undergoing ICSI procedures. Published data related to carrier frequency of the -308A allele in the general French population report a frequency ranging from 22 to 28%. The two most recent French studies reported frequencies varying from 22 (Berrahmoune et al., 2007) to 28% (Meirhaeghe et al., 2005) , with an average frequency $25%. Since the fertility status of this general French population is not known, we considered patient Group IV (A2T2), which exhibited a normal sperm count with no alteration of sperm motility and morphology, as a control group in our present study. On the basis of these criteria, the results show that the frequency of the -308 allele was significantly higher in infertile patients with testicular failure (30.9%) or with altered sperm motility (33.9%) compared with patients with normal sperm parameters (19.4%). An increased frequency in the patient group with testicular failure was also observed when compared with the patient group with Table IV . Influence of polymorphism on hormone levels in Groups I and II. Comparison of G/G versus A/G or A/A for each group. decreased sperm count due to an obstructive origin (Group I). Although Group I exhibited a relatively low TNFa polymorphism (13.2%), this is not statistically different from that of the control group (Group IV A2T2, 19.4%) with normal sperm parameters (Table II) . The infertile patients studied here are from two French cities, Paris (62.4% of the population) and Lyon (37.6% of population), with two predominant ethnic origins, Caucasian (84.4%) and North African (14.5%). When TNFa polymorphism was analyzed solely in the Caucasian population, the data obtained concerning TNFa polymorphism distribution in the different infertility subtypes were quite similar to those obtained in the entire population. Indeed, a higher incidence of TNFa polymorphism was observed in patients with testicular failure (31.2%) or with altered sperm motility (35.8%) when compared with patient with normal sperm parameters (17.7%). Owing to the limited number of North African patients, statistical analyses of this population were not meaningful. These observations suggest that the TNFa polymorphism distribution reported here in the different subtypes of infertile males is nonetheless meaningful for the Caucasian population. Together, these observations indicate that compared with control group patients with normal sperm parameters, we observed an increased frequency in infertile patients with decreased sperm count (due to testicular failure) or altered motility. Although this cytokine polymorphism appears to decrease in patient groups with altered sperm count due to obstructive origin, its frequency was not different from that of the control group, i.e. patients with normal sperm count and quality.
The present results suggest the existence of a potential link between the 2308A allelic type and alterations in both spermatozoa production and sperm motility. Assuming that cytokine expression increases in the presence of the 2308A allelic type, our present observations also raise the possibility of a new use of the anti-TNFa agents in male infertility, since it is now generally accepted that the 2308 TNFa polymorphism is associated with increased TNFa expression/production. Although in in vitro systems (Wilson et al., 1997; Uglialoro et al., 1998) , there is some controversy as to whether the 2308 TNFa polymorphism induces an increase in TNFa production, in vivo studies (Warzocha et al., 1998; Gonzalez et al., 2003; Heesen et al., 2003) have clearly established a positive correlation between the polymorphism and an increase in cytokine levels.
TNFa is a pleiotropic cytokine that has been implicated in many cellular system activities (Hehlgans and Pfeffer, 2005) . This cytokine provides a rapid host defense against infection, but is fatal in excess. TNFa also affects lipid metabolism, coagulation, insulin resistance and endothelial function, as well as the hypothalamo-pituitary axis. Cytokines, and particularly TNFa, have been widely reported to interact with the endocrine system in the control of testicular functions, at least in experimental (rat, mouse and porcine) models. Several cytokines have direct effects on testicular functions; a number of these, such as TNFa, are produced within the testis even in the absence of inflammation or immune activation events. There is compelling evidence that TNFa plays an important regulatory role in the development and normal function of the testis (Mauduit et al., 1993 (Mauduit et al., , 1998 Benahmed, 1996; Huleihel and Lunenfeld, 2004) . TNFa has a direct role in the response to gonadotrophins LH and FSH and in the blood -testis barrier (Hellani et al., 2000; Wong and Cheng, 2005) . Consequently, local and systemic up-regulation of cytokine expression may contribute to the disruption of testicular functions and fertility. Therefore, in the present study, the patient's hormonal status was studied by evaluating plasma levels of FSH, inhibin B, LH, T and SHBG. As expected, the hormonal pattern was affected only in Group II patients displaying non-obstructive oligo-or azoospermia but not in the other groups. Interestingly, with regard to the -308 TNFa polymorphism, a higher plasma level of inhibin B and a lower plasma level of FSH were found in Group II patients with the 2308A allele compared with patients carrying the 2308G allele. Specifically, the ratio of FSH to inhibin B was almost halved in patients with the 2308A allelic type. Furthermore, these alterations in FSH, inhibin B and free testosterone plasma levels appeared more pronounced in the patients with A/A compared with A/G genotypes, suggesting a possible allelic rate influence on hormone levels. The mechanisms underlying these changes in the plasma gonadotrophin FSH and inhibin B levels in oligo-or azoospermic patients with the 2308A allele remain unclear. However, the possibility exists that in the patients bearing this variant allele, the normal adaptive changes of the endocrine system needed to correct a spermatogenetic process failure might be disrupted, independently of etiology. It is generally assumed that spermatogenetic process failure is associated with a decrease in inhibin B levels, which triggers an increase in FSH levels in order to stimulate the spermatogenic process. In the presence of the 2308A allele, the levels of inhibin B remained relatively higher compared with oligo-or azoospermic patients with the 2308G allele. Sustained higher levels of inhibin B may limit the (beneficial) rise in FSH levels, which would be insufficient to correct the altered spermatogenetic process. For these reasons, we suggest that the relative alteration of these corrective mechanisms in patients carrying the 2308A allele could favor a progressively chronic failure of the spermatogenic process.
In addition, the relative increase in TNFa polymorphism frequency in infertile patients was associated with asthenospermia in the absence of genital infection. In this context, it should be noted that TNFa has been reported to modify sperm motility. For example, TNFa in vitro causes a significant reduction in both progressive and total sperm motility (Eisermann et al., 1989; Estrada et al., 1997) . The addition of polyclonal rabbit anti-TNFa antibody (Eisermann et al., 1989) or the addition of Inflimab, an anti-TNFa drug (Said et al., 2005) , reverses this inhibitory effect on sperm motility. A recent study has also shown that sperm motility is enhanced when cytokines are inactivated in seminal plasma (Cohen et al., 2004) . Although the mechanisms of action of the cytokine on sperm quality (particularly on motility) remain to be elucidated, cytokines, and particularly TNFa, can induce reactive oxygen species formation, which may be a significant cause for sperm quality alteration leading to male infertility (Lemkecher et al., 2005) . Although the -308 TNFa polymorphism does not affect fertility, the cytokine polymorphism may represent a susceptibility factor, which, with other factors (epigenetic, environmental), could provoke alteration of male fertility.
In addition to the -308 TNFa polymorphism, we have also determined the frequency of the -238 TNFa polymorphism. In contrast to -308 SNP, no significant association was observed between the frequency of -238 TNFa polymorphism and the different types of male infertilities. It is noteworthy that -238 TNF polymorphism was not associated with change in TNF expression or production (Pociot et al., 1995) .
Finally, as the 2308A allele appears to be associated in vivo with increased TNFa expression/production, the potential use of anti-TNFa agents for male infertility appears plausible. On the basis of the present findings, these biological response modifiers (which neutralize TNFa and/or block its signal transduction downstream) could possibly benefit infertile patients. Specifically, these would be two subsets of infertile men: those with reduced sperm production (i.e. with primary testicular dysfunction) or those with decreased sperm motility. These potential therapies could be used alone or in combination with ART in the two subsets of patients identified here.
